ABSTRACT
This study compares the serological antibody level post-COVID-19 vaccine among healthy subjects and psychiatric patients on antidepressant therapy. It also examines the difference in antidepressants' side effects experienced by psychiatric patients following the completion of two vaccine doses. A comparative posttest quasi-experimental study was conducted among healthy subjects and psychiatric patients on antidepressant medication in a teaching hospital in Malaysia. Elecsys Anti-SARS-CoV-2 assay was used to detect the antibody titre between weeks 4 and 12 post vaccination. The antidepressant side-effect checklist (ASEC) was used to monitor the occurrence of antidepressant-related side effects pre-and post-vaccination. 24 psychiatric patients and 26 healthy subjects were included. There was no significant difference in the antibody level between the patients (median = 1509 u/ml) and the healthy subjects (median = 995 u/ml). There was no significant worsening in the antidepressant-related side effects. The antibody level post-COVID-19 vaccine did not differ significantly between patients on antidepressant therapy and healthy subjects. Additionally, there was no change in the antidepressant side effects experienced by the patients following the completion of the vaccine.Copyright © 2022, Research Trends (P) LTD.. All rights reserved.
ABSTRACT
The prevalence of psychiatric disorders namely depression, anxiety, and sleep disturbances has been increased worldwide, particularly during the COVID-19 pandemic. In this regard, the interest of recent investigations is moved toward phytomedicines and bioactive substances derived from natural sources. Although Tilia platyphyllos Scop. contains high amounts of phenolic compounds such as quercetin, kaempferol, and catechin, there is no study on the possible effects of its extract on psychological disorders. The present study was carried out to determine the antidepressant-like, anxiolytic, and sedative-hypnotic effects of the hydroethanolic extract of T. platyphyllos leaves using forced swimming test (FST), tail suspension test (TST), elevated plus maze test (EPMT), pentobarbital-induced loss of righting reflex test and open field test (OFT). Following the ethanolic extraction of T. platyphyllos leaves, the extraction yield was 14% and the total phenolic and total flavonoid contents were found to be 135.23 +/- 0.14 mg gallic acid equivalent/g dry extract and 19.02 +/- 0.03 mg rutin equivalent/g dry extract, respectively. Both FTS and TST revealed a significant antidepressant-like activity for the tested extract at 400 mg/kg compared to the control group. In addition, the anxiolytic activity of the extract was proven through OFT and EPMT in the same dose. Finally, T. platyphyllos extract at 200 mg/kg and 400 mg/kg significantly increased the sleeping time when compared to the control group reflecting its potential hypnotic activity. Co-administration of T. platyphyllos extract at 400 mg/kg and flumazenil as the GABA-A receptor antagonist decreased the sleeping time but the observed effect was not statistically significant. Therefore, we cannot completely rule out the GABA-A receptor's involvement in the hypnotic activity of the extract. The biological results presented here led us to conclude that T. platyphyllos extract can be a prominent source of antidepressant, anxiolytic and hypnotic agents. Probably, the main phenolic compounds of T. platyphyllos such as quercetin, kaempferol, and catechin are involved in the observed effects. However, there is still a great need for additional investigations on the exact mechanisms.Copyright © 2022, Iranian Association of Pharmaceutical Scientists. All rights reserved.
ABSTRACT
The proceedings contain 96 papers. The topics discussed include: practical pharmacotherapy for opioid use disorder in the age of fentanyl;can COVID-19 cause acute psychosis in pediatric patients? a case report;a survey of bullying experiences in a child and adolescent psychiatric clinic population;acute emergence of suicidal thoughts following Lemborexant initiation: an adverse reaction case report;assessing the unmet clinical need and opportunity for digital therapeutic intervention in schizophrenia: perspective from people with schizophrenia;rapid antidepressant effects and MADRS item improvements with AXS-05 (DEXTROMETHORPHAN-BUPROPION), an oral NMDA receptor antagonist in major depressive disorder: results from two randomized double-blind, controlled trials;targeting lncRNA NEAT1 impedes Alzheimers disease progression via MicroRNA-193a mediated CREB/BDNF and NRF2/NQO1 pathways;and impact of AXS-05 (DEXTROMETHORPHAN-BUPROPION), an Oral NMDA receptor antagonist, on Anhedonic symptoms in major depressive disorder.
ABSTRACT
Background: Physical activity (PA) has shown to have beneficial effects on children's health and development. However, a reduced focus on PA programming in schools and home environments may contribute to the increasing prevalence of mental health problems among youth, particularly following the onset of the COVID-19 pandemic. Here, we report preliminary findings from an ongoing randomized controlled trial of acute exercise (light-intensity or moderate-intensity) and meditation on mood and affect in youth. Method(s): Youth participants recruited from the Metro Detroit area (N =25: 52% female, 48% black;Mean + SD age =12.92 + 2.18yrs) were randomly assigned to a single 30-minute session of either (1) moderate-intensity treadmill walking, (2) light-intensity stretching, or (3) a seated meditation session. Mood and positive and negative affect were measured pre- and post-session. Result(s): There was a pre-to-post-session reduction in negative mood and affect scores and an increase in positive affect (p's<0.05, d's 0.42-0.67). However, no significant main effects of condition or condition x time interaction were observed (p>0.05). Youth with higher negative baseline mood scores showed greater reductions in negative mood following the 30-minute session, as compared to youth with lower negative moods (r=0.87, p< 0.001). Conclusion(s): Acute light and moderate-intensity exercise, as well as meditation, were associated with reductions in negative mood and affect and increases in positive affect. Further, the antidepressant effects of acute exercise and meditation were more pronounced among youth with poorer baseline moods. These findings have implications for the use of PA and meditation-based interventions to combat mental health problems in youth. Funding Source: Wayne State University, National Institute of Mental Health, and the Eunice Kennedy Shriver National Institute of Child Health and Human Development Keywords: Affect, Adolescent Depression, Mental health, exercise intervention, Mindfulness MeditationCopyright © 2023
ABSTRACT
E-Mental Health in older age Ulrich Hegerl, Caroline Oehler Department of Psychiatry, Psychosomatics, and Psychotherapy, Goethe Universitat Frankfurt/M, Germany European Alliance against Depression e.V. (www.EAAD.net) The implementation and uptake of digital tools for self management or psychotherapy for people suffering from depression or other mental disorders has gained momentum during the Covid-19 pandemia. While studies using waiting list or treatment as usual control groups are of limited value, meta-analyses of RCTs with face-to-face psychotherapy as control condition have found a comparable antidepressant effect, especially when the interventions were provided together with professional guidance. The iFightDepression-tool offered by the European Alliance against Depression (EAAD) is available in 10 different languages and is broadly used in several European countries. Data will be presented concerning the attitude of older people concerning iCBT and also concerning effects of age, guidance, and gender on both adherence to the iFightDepression-tool and antidepressant effects.
ABSTRACT
Donepezil hydrochloride is an acetylcholine esterase inhibitor studied and approved to treat Alzheimer’s disease (AD). However, this drug can have positive therapeutic potential in treating different conditions, including various neurodegenerative disorders such as other types of dementia, multiple sclerosis, Parkinson’s disease, psychiatric and mood disorders, and even infectious diseases. Hence, this study reviewed the therapeutic potential of this drug in treating Alzheimer’s and other diseases by reviewing the articles from databases including Web of Science, Scopus, PubMed, Cochrane, and Science Direct. It was shown that donepezil could affect the pathophysiology of these diseases via mechanisms such as increasing the concentration of acetylcholine, modulating local and systemic inflammatory processes, affecting acetylcholine receptors like nicotinic and muscarinic receptors, and activating various cellular signaling via receptors like sigma-1 receptors. Despite many therapeutic potentials, this drug has not yet been approved for treating non-Alzheimer’s diseases, and more comprehensive studies are needed.
ABSTRACT
Introduction: Psychedelics have seen various labels: mystical sacrament aids, potential interrogation tools for the Cold War, agents for social change in the Hippie counter movement, a panacea for various mental disorders, and a tool to “hack” of the psyche. This has led to their reputation as both societal threat and a psychopharmacological breakthrough. After the loss of data on over 1000 clinical papers spanning 40000 study subjects in the 60′s, a 40-year hiatus, and a few very determined researchers, new insights of increasingly quality have been emerging from research on the potential benefits of the use of psilocybin in depression. We aim to review available data on psilocybin for treating depression, providing a bird's-eye view on the literature (historical and current), while reporting potential neurobiological, psychological and cognitive mechanisms involved, safety and methodological concerns (as well as recent advancements), emerging modalities of treatment, with a commentary on social and cultural movements occurring in parallel to the scientific endeavor to create regulated and scientifically approved treatments. Methods: Eligible studies will be identified through an electronic search of Medline and clinicaltrials.gov from inception to the date of submission. The search strategy will combine relevant standardized subject terms and text words for psychedelics, psilocybin, and depression, with relevant Boolean operators implemented. Only articles written in the English language will be included. Reference lists from eligible studies will be cross-checked to identify potential additional studies. For data synthesis, results and outcomes will be explored narratively, along reporting and critical analysis of relevant statistical data. Results: Psilocybin emulates serotonin, with special affinity for the 5-HT2A receptor. Neuroimaging studies suggest an attenuation of the default mode network and an overall increase in multiple brain area connectivity [1]. Current treatment models involve previous psychological profiling and preparation, followed by one to two sessions where administration of 25 mg of psilocybin under supervision and support from the researcher, a physician, and a therapist, with post-treatment integration. Since 2011, five clinical studies, evaluated psilocybin treatment efficacy on patients suffering from clinical depression [2,3,4]. Limited by small samples, variability of setting, timeline, and methodology, they combined number of 139 patients. Despite these limitations, 60% of patients reported significant symptom reduction (58-83%) providing promising preliminary evidence for further investment. A recent trial found no significant difference in antidepressant effects between psilocybin and escitalopram in a selected group of patients, further contributing to this trend of research [5]. Over 50 studies addressing effects of psilocybin in depression have been approved on clinicaltrials.gov. One of these [6] is a phase 2 multicentered clinical trial, aiming to further evaluate the safety and efficacy of psilocybin in treatment resistant depression in a variable dose range. Conclusion: Psilocybin might become a promising approach to depression. These therapies have been (re)gaining social and cultural support, with parallel “off label” use in various spiritual and psychotherapeutic settings. There is a need for the upmost rigor in designing future research. Psilocybin might emerge as an important therapeutic tool for current and upcoming global mental health challenges in a post-COVID-19 world. No conflict of interest